Seasonal depression in T-allele carriers is a receptor lag rather than a serotonin problem: GR sensitivity cannot adjust fast enough to track changing photoperiod, and the resulting cortisol-glutamate deficit converges on overactive GSK3β, the same molecular endpoint as burnout and chronic mismatch. Winter depression and spring hypomania are two sides of a coupled oscillation, and treating one without managing the other guarantees recurrence.
The seasonal vulnerability described in this section is a side effect of the same slow receptor adjustment dynamics that produce the beneficial depth of hyperfocus (Part 2) and the crisis-survival capacity of the storm response (Part 3), not an independently adaptive feature. The FKBP51-mediated feedback lag cannot be selectively fast for photoperiod tracking and slow for everything else: it is a single mechanism with consequences at every timescale. The lock-in that makes hyperfocus productive and the absorption that sustains function during extreme stress come from the same sluggish feedback that makes seasonal receptor adjustment too slow to track shortening days. You cannot have the benefits described in Parts 2 and 3 without the vulnerability described here.
The same FKBP51-mediated slowing that produces acute hyperfocus on a timescale of hours produces two additional phenomena when operating on the timescale of weeks to months: seasonal mood variation and burnout vulnerability. These are mechanistically related, as both involve GR receptor density failing to adjust quickly enough to match a changing cortisol environment, but are driven by different inputs (photoperiod versus stress exposure).
GR receptor density is not static. Cells continuously adjust receptor count and sensitivity in response to their cortisol environment. Sustained high cortisol drives GR downregulation through multiple documented mechanisms: epigenetic silencing of the NR3C1 gene via promoter methylation (Palma-Gudiel et al., 2015), cytokine-driven receptor degradation (Webster et al., 2001), BDNF depletion reducing GR maintenance (Numakawa et al., 2009), and direct receptor internalization. Conversely, reduced cortisol exposure allows GR to upregulate — receptor density increases and sensitivity improves.
This adjustment process is itself GR-mediated. Cells need to detect cortisol levels via GR to know whether to up- or downregulate receptor density. In T-allele carriers, every step of this detection runs through the FKBP51 buffer. The adjustment is slower. A gap opens between the current receptor state and the receptor state that would match the current cortisol environment. This lag is the mechanism underlying both seasonal depression and prolonged burnout recovery.
Animal evidence for photoperiod-driven GR changes. The claim that photoperiod drives GR adjustment is not purely theoretical. In white-footed mice, short photoperiod increases glucocorticoid receptor gene expression in the hippocampus and enhances sensitivity to dexamethasone-mediated suppression of corticosterone (Pyter et al., 2005). In Fischer 344 rats, photoperiod regulates corticosterone rhythms through changes in adrenal sensitivity to ACTH, and this regulation operates through melatonin-independent mechanisms (Ishida et al., 2012), meaning it cannot be fully explained by the circadian/melatonin models that dominate current SAD research. These findings establish that photoperiod directly modulates glucocorticoid signaling parameters in mammals, which is the foundational claim of the seasonal lag model.
FKBP51 and circadian rigidity. Recent evidence directly connects FKBP51 levels to the timescale of rhythmic adjustment. Gebru et al. (2025) overexpressed FKBP51 in the corticolimbic system of mice and found, surprisingly, greater circadian rhythm amplitude and decreased rhythm fragmentation — particularly in females, who also showed higher corticosterone levels both basally and following stress. The companion study (Gebru et al., 2024) found the inverse: Fkbp5 knockout mice were protected from stress-mediated circadian disruption, meaning the absence of FKBP51 made the system more adaptable to perturbation.
These findings appear paradoxical — if FKBP51 stabilizes circadian rhythms, why would T-allele carriers have worse seasonal adjustment? The resolution is that stability and adaptability are opposing properties. A more rigid, high-amplitude oscillator resists perturbation more strongly. This is exactly what the lag model predicts: the T-allele system does not adjust quickly to changing photoperiod because its operating parameters resist change. Greater circadian amplitude means more inertia, and more inertia means more lag when the input signal shifts. Gebru's data is the circadian-level expression of the same sluggish feedback dynamics described at the receptor level throughout this paper.
SAD in T-allele carriers is driven by GR receptor sensitivity failing to track changing photoperiod — not by serotonin deficiency. No study, to our knowledge, has examined the role of FKBP5 genotype in seasonal mood variation.
Seasonal affective disorder (SAD) is conventionally attributed to disruptions in serotonin levels, melatonin secretion, and circadian rhythm misalignment (Rosenthal et al., 1984).
Why the cortisol-SAD literature has stalled. A systematic review by Agustini et al. (2019) found insufficient evidence to classify SAD as a hypocortisolemic condition, despite anecdotal characterization as such. The strongest finding was that SAD patients demonstrate an attenuated cortisol awakening response (CAR) in winter but not in summer (Thorn et al., 2011). The reviewers noted that the number of SAD-HPA axis studies has declined over time, and the field appears to have moved on without resolution.
This inconsistency is exactly what the threshold model predicts. Functional cortisol signaling depends on the interaction of at least four variables: (1) circulating cortisol concentration, (2) FKBP5 genotype, (3) childhood adversity history, and (4) recent photoperiod history, which determines the current state of GR sensitivity. A SAD cohort mixing CC, CT, and T/T carriers with different childhood histories and different recent light exposures will inevitably produce noisy results when cortisol alone is measured. Stratifying by genotype and childhood adversity would be expected to resolve much of the existing contradiction.
The lag model. In CC carriers with efficient GR feedback, receptor sensitivity adjustment tracks the gradual seasonal light change closely. Net cortisol signaling remains roughly constant across seasons. In T-allele carriers, the adjustment lags. As days shorten in autumn, GR sensitivity cannot upregulate fast enough to compensate for declining cortisol signaling. The effective cortisol signal drops, GSK3β becomes less suppressed, and the downstream glutamate deficit widens. A gap opens. At some point in October or November, the cumulative lag pushes effective signaling below the activation range. The transition feels sudden because the compressed functional range (Part 2) converts a continuous decline into what feels like a binary switch.
Once below threshold, the individual remains stuck for the duration of winter. The GR sensitivity upregulation that would close the gap is itself slowed by the same FKBP51-mediated feedback dynamics that slow all GR adjustment in T-allele carriers, creating a self-reinforcing trap.
Retinal amplification: a second lag mechanism. The receptor lag is compounded by a sensory input lag at the retina itself. Photoperiod regulates retinal dopamine synthesis: short photoperiod suppresses expression of the tyrosine hydroxylase gene (TH) in the retina, reducing dopamine production and decreasing retinal photosensitivity (Yamamoto et al., 2021). SAD patients show reduced retinal sensitivity in winter, and this reduction correlates with symptom severity. The mechanism creates a feedback loop: shorter days reduce retinal dopamine, the retina becomes less sensitive to the light that remains, the effective light signal reaching the brain is further attenuated, and the already-weakened cortisol signal driven by light falls even further below the FKBP5-elevated threshold. For a T-allele carrier whose effective cortisol signaling is near the activation cliff, this retinal attenuation may be the difference between barely clearing threshold and falling below it. Yamamoto et al. demonstrated that pharmacological rescue of retinal dopamine signaling restored photosensitivity in short-day mice, suggesting that the retinal component is independently targetable.
Spring overshoot. In spring, the reverse occurs asymmetrically. After months of low light, receptors have finally sensitized to winter conditions. As days lengthen rapidly in March and April, increasing light drives stronger cortisol signaling into these highly sensitized receptors. The effective signal overshoots the threshold. Because receptor desensitization also lags, the overshoot persists for weeks — producing elevated energy, reduced sleep need, increased confidence, rapid ideation, and impulsive decision-making, clinically indistinguishable from hypomania. Spring hypomania in bipolar disorder is well-documented but poorly explained by existing models (Goodwin & Jamison, 2007). If it is a receptor lag phenomenon exacerbated by FKBP5 dynamics, this connects seasonal mood disorders to the stress genetics literature in a way not previously proposed.
Why the serotonin and dopamine focus has been misleading. Cortisol is upstream of serotonin, dopamine, glutamate, GABA, endocannabinoids, and acetylcholine (see Part 1). A disruption in GR-mediated cortisol signaling therefore produces simultaneous downstream dysregulation across multiple neurotransmitter systems — and FKBP51's direct stripping of glutamate receptors adds an independent deficit on top. The inconsistent dopamine and serotonin findings across SAD studies reflect heterogeneous downstream expression of a single upstream problem. Researchers measuring dopamine or serotonin without accounting for upstream cortisol signaling dynamics and FKBP5-mediated glutamate receptor depletion are measuring individual branches while ignoring the trunk.
Direct evidence that GR mediates the mood effects of light patterns has recently emerged. Chou et al. (2024) demonstrated in rats that light exposure at night induced depression-like behavior and reduced BDNF expression in the medial prefrontal cortex and periaqueductal gray through a GR-dependent mechanism: pharmacological GR activation mimicked the depression-like effects of aberrant light exposure, while GR antagonism blocked them. This confirms that the mood consequences of disrupted light patterns run through glucocorticoid receptors, not solely through melatonin or serotonin — which is the central claim of the seasonal lag model.
This explains why SSRIs partially improve mood in some SAD patients but do not resolve fatigue, anhedonia, or cognitive impairment. The upstream problem — GR sensitivity lag — is not addressed by patching one downstream branch.
Bidirectional seasonal management. A critical and novel implication: the seasonal crash and seasonal surge are causally linked through receptor dynamics. Winter depression occurs because receptors could not sensitize fast enough as days shortened. But the reason they needed to sensitize so far is that they had fully desensitized during the preceding summer. Conversely, spring hypomania occurs because receptors are maximally sensitized from winter.
This means the treatment target is the amplitude of the annual receptor sensitivity oscillation, not winter depression per se. Limiting summer desensitization (reduced peak light exposure) reduces the adjustment needed in autumn. Supplementing winter light reduces extreme sensitization and attenuates spring overshoot. The disorder is a coupled oscillation, and intervening at either peak reduces the amplitude of both, structurally analogous to bipolar disorder management.
This is, to our knowledge, a novel treatment framework. Existing SAD treatment focuses exclusively on winter intervention. The receptor lag model predicts that summer light management is equally important.
GSK3β as the convergent endpoint. The receptor lag model explains WHY seasonal depression occurs — GR sensitivity cannot track photoperiod. But the functional deficit that produces the subjective experience of seasonal depression is downstream of GR: it is overactive GSK3β. When GR is insufficiently activated during low-light months, it fails to suppress GSK3β through the PI3K/Akt pathway. Unopposed GSK3β then suppresses presynaptic glutamate release (Zhu et al., 2007), actively removes AMPA receptors from synaptic surfaces via the kinesin motor system (Du et al., 2010), degrades BDNF signaling, and drives dendritic spine retraction. The glutamate synapse is impaired on both sides: less signal released and fewer receptors to receive it. The glutamate suppression is critical: because glutamate is required for dopamine, serotonin, and norepinephrine neurons to fire (Part 1), overactive GSK3β produces simultaneous dysfunction across all downstream neurotransmitter systems through a single bottleneck.
The subjective experience of overactive GSK3β is like wearing sunglasses you cannot remove — glutamate release is suppressed, AMPA receptors are being actively pulled off synaptic surfaces, and the downstream neurotransmitters that depend on glutamate signaling are underperforming. The world feels dim and flat. When GSK3β is suppressed, glutamate release normalizes, AMPA receptor removal slows, and the sunglasses come off.
This means seasonal depression, burnout-related anhedonia, and the chronic flatness of T-allele carriers with childhood adversity may all converge on the same molecular endpoint: overactive GSK3β suppressing tonic glutamate. They feel subjectively identical because they ARE the same downstream event — insufficient glutamate to drive dopamine, serotonin, and norepinephrine systems — produced by different upstream causes (insufficient light, GR desensitization, or permanent threshold elevation, respectively).
Lithium orotate inhibits GSK3β directly, without requiring cortisol, GR, or adequate photoperiod. It may treat seasonal depression not by fixing the light problem or the receptor lag but by suppressing the molecule that the entire upstream chain was trying to suppress. For a T-allele carrier, lithium orotate combined with summer light management would address both the downstream target (GSK3β) and the oscillation amplitude (receptor dynamics) simultaneously — a more complete intervention than either alone. For a detailed analysis of GSK3β as the convergent target of multiple antidepressant mechanisms, see GSK-3B.com.
GSK3β inhibition as a light therapy amplifier. This has an immediate clinical implication for existing SAD treatment: GSK3β inhibition should make light therapy more effective. Current light therapy protocols focus entirely on the input — lux levels, timing, duration. Nobody is addressing the receiver. If overactive GSK3β both suppresses glutamate release in the visual cortex and strips the AMPA receptors that would transduce the remaining signal, then a patient sitting in front of a 10,000-lux light box with overactive GSK3β is receiving a fraction of the effective signal that the same light box would deliver with GSK3β properly suppressed. Adding lithium orotate to an existing light therapy protocol would not change the photons entering the eye. It would change how much signal those photons produce. The same light box works better because the brain can hear it. This is a trivially testable hypothesis: compare light therapy response rates in SAD patients randomized to light therapy alone versus light therapy plus lithium orotate.
The virtuous cycle hypothesis: GSK3β inhibition may increase cortisol production. What follows is an inference chain; no step has been demonstrated in T-allele carriers. Bright light exposure in the early morning increases cortisol secretion by more than 50% through the retinal → SCN → HPA axis pathway (Leproult et al., 2001), and this effect is mediated by melanopsin-expressing retinal ganglion cells that are sensitive to light intensity. The retinal amplification mechanism described above suggests a degenerative loop: overactive GSK3β → reduced sensory cortex gain → attenuated light signal → less cortisol production → less endogenous GSK3β suppression → further GSK3β overactivation. The loop runs in reverse under GSK3β inhibition: restored visual cortex gain amplifies the light signal reaching the SCN, driving more cortisol production, which provides more endogenous GSK3β suppression through the GR → Akt pathway. The sunglasses come off, the sun drives cortisol, and cortisol keeps the sunglasses off.
If this virtuous cycle operates, lithium may not be a lifelong intervention for the seasonal component. It may be a kick-start: suppress GSK3β long enough for sensory gain to normalize, allow the amplified light signal to restore adequate cortisol production, and let the endogenous system maintain itself once the cycle reverses. This is a testable prediction: T-allele carriers taking lithium orotate should show measurable increases in morning cortisol over weeks, driven by increased photic sensitivity rather than by any direct effect of lithium on the HPA axis. Cortisol curves should steepen before the lithium dose is reduced, and the gains should persist after tapering if the sensory amplification is self-sustaining.